The incidences of the composite primary outcome at a mean follow-up of 1.6 years were 3.2 % ( 2.02 % per year ) in the aspirin group compared to 6.1 % ( 3.84 % per year ) in the vitamin K antagonists group with an absolute advantage of 2.9 percentage points .